Australia's largest stock trading and investment forum Australia's #1 stock forum

RAP

Click for more information

0.00%

20.5¢ resapp health limited

Ever heard of Bill Gates? He has a few billion. Let’s see what...

First 931 Last

Share
Profile

Follow
green8

307 Posts.

578

06/08/18

23:33

Post #: 34760640
Share

Originally posted by Southoz ↑

RSH (ISN) was Australia’s first mHealth train wreck. RAP has made a pretty good crack at being the second.

Like many of the companies in this space RSH began its life journey with the “diagnosis” idea – after all wheeze is a cardinal feature of asthma. This proved (for various reasons) to be a bit of a dead end and the company pivoted to the notion that monitoring wheeze might be useful.

The value of monitoring wheeze unfortunately also turns out to be unclear. And so in the final metamorphosis the company moves to the generic chronic disease type management ecosystem “big data” type idea.

Investors will unfortunately find that this is virtually worthless – anyone can do this and everyone is.

RAP I think will follow this exact path if diagnosis proves too difficult.

As posters (above) have recalled in 2016 RAP started talking about the idea of “expanding” its portfolio from diagnosis to management of respiratory disease. And in fact has developed an algo to calculate wheeze severity scores.

In micro-cap speak “expanding the portfolio” is code for we failed at what we were first trying to do but now we have another solution in search of a problem. RAP must have been trying to get in early ….

RSH I think has had its day. Having said that billionaires (BM) can do wonderful things to the share price of a micro-cap. So its anyone’s guess really.

For RAP the job ahead is pretty simple.

To date RAP has not made one single successful prediction from a cough sound to the diagnosis of any respiratory disease using a model that had not been trained on data from that particular cough sound.

And the first time it tried to do this (the first US trial) it failed comprehensively - on everything. Which was lucky … because it meant that the failure in the external validity of actual algo could be buried. And so everyone can continue to believe the technology “works” and problem was just nurses making cough recordings.

The actual extent to which RAP has actually been modelling signal as opposed to noise will all be cleared up shortly. And so we will all see.

In answer to the question.

RAP and RSH I think are indirect competitors in the sense that the retail dollar is limited for this niche sector. And dollars are split between RAP / RSH / NTI / MEB / PCK to name a few.

If diagnosis proves too difficult for RAP then yes it will become a direct competitor in the using “technology for the management of disease symptoms” idea. In which case RSH will prevail because it has a billionaire and RAP doesn’t.

Expand

Ever heard of Bill Gates? He has a few billion.
Let’s see what the results show.

RAP Price at posting: 18.0¢ Sentiment: Buy Disclosure: Held
2 Upvote

0 Great analysis

Reply

There are more pages in this discussion • 2,518 more messages in this thread...

First 931 Last

Add RAP (ASX) to my watchlist